Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI

Inclusion Criteria: 1. Virologically suppressed for at least 48 weeks prior to study entry 2. Coming from a regimen containing Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF), Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC), or, Dolutegravir/Tenofovir Disoproxil Fumarate/Emtricitabine (DTG+TDF/FTC) with no known failures to integrase inhibitors for al least 48 weeks. 3. BMI ≥25 kg/m2 at screening and 4. Unintentional weight gain of \>10% from baseline (prior to INSTI initiation) within 1-3 years of starting INSTI ART, with no other apparent medical reason to explain the weight gain (concomitant medication use, Cushing's disease, recent prolonged hospitalization, etc.), in the opinion of the site investigator. 5. Body fat percentage \>20% 6. No indication or plans to add or change medications associated with significant weight change during the study period. 7. Participants currently receiving antipsychotics, antidepressants, anticonvulsants/mood stabilizers, and thyroid replacement hormones without dose modifications for at least 12 weeks prior to randomization 8. Participants currently receiving antidiabetics known to cause weight loss and without dose modifications for at least 24 weeks prior to randomization (GLP-1 receptor agonists, SGLT-2 inhibitors, insulin, metformin). 9. Agree to adhere to assigned ART during the study period 10. HIV-1 RNA screening \<50 copies/mL performed within 45 days prior to study entry. 11. GFR by CDK-EPI ≥60 mL/min 12. Alanine aminotransferase (ALT) and asparatate aminotransferase (AST) \< 90 IU/L 13. Thyroid profile (TSH, free T3 and free T4) prior to entering the study 14. Serum and urinary electrolytes, cystatin C, prior to entering the study Exclusion Criteria: 1. Loss of social security 2. Allergy to any of the components of ART, previously unknown. 3. Withdrawal of informed consent 4. Acquiring HBV and/or HCV infection during follow-up. 5. HIV-1 RNA \>200 copies/mL in 2 consecutive determinations after having achieved virological suppression. 6. Early initiation or discontinuation of any of the following drugs after entering the study: antipsychotics (clozapine, olanzapine, risperidone); antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors) monoamine oxidase inhibitors, associated with weight gain; anticonvulsants/mood stabilizers (lithium, valproic acid) or associated with weight loss (topiramate); thyroid replacement hormones; 7. Change in dose or discontinuation of antidiabetic drugs that cause weight loss (GLP-1 receptor agonists, SGLT-2 inhibitors, insulin, metformin), after entering the study. 8. Planning to undergo or having undergone bariatric surgery. 9. Initiating significant dietary changes, advised by a nutritionist according to what was reported by the participant 10. Initiating or increasing physical exercise or enrolling in a structured weight loss regimen: \<250 minutes/week of moderate to intense activity